GP-Act III Acquisition Corp. (NASDAQ:GPATW – Get Free Report) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 2,294 shares, a decrease of 47.8% from the September 30th total of 4,397 shares. Based on an average daily trading volume, of 13,742 shares, the short-interest ratio is presently 0.2 days.
GP-Act III Acquisition Stock Performance
Shares of NASDAQ GPATW traded down $0.00 during midday trading on Monday, reaching $0.07. 239 shares of the company were exchanged, compared to its average volume of 22,263. GP-Act III Acquisition has a 1 year low of $0.03 and a 1 year high of $0.43. The stock has a fifty day simple moving average of $0.10 and a 200 day simple moving average of $0.18.
GP-Act III Acquisition Company Profile
GP-Act III Acquisition Corp. is a special purpose acquisition company (SPAC) formed to identify and complete a merger, capital stock exchange, asset acquisition, or similar business combination with one or more operating companies.
As a blank-check company, GP-Act III Acquisition Corp. does not currently operate a commercial business or offer products and services of its own. Its activities are focused primarily on evaluating potential acquisition targets and pursuing a transaction that would result in a publicly traded operating company.
GPATW represents the company’s publicly traded warrants, which are securities that may provide holders with the right to purchase shares under specified terms.
See Also
- Five stocks we like better than GP-Act III Acquisition
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for GP-Act III Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GP-Act III Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
